EZH2 and neoplasm: For example, overexpression of wild-type (WT) EZH2, and subsequent increases in H3K27me3, have been described in several non-hematological cancers, including prostate and breast cancer [41,42,43,44], where evidence suggests that the increased H3K27me3 levels promote tumor progression and metastasis.